Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of OCU400 in Inherited Retinal Disease

Next Previous
X
Search
Trial Profile

A Phase I/II Study of OCU400 in Inherited Retinal Disease

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OCU 400 (Primary)
  • Indications Retinal degeneration; Retinal disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ocugen

    • Most Recent Events

    • 06 Jan 2022 According to an Ocugen media release, this trial is expected to initiate in Q1 2022.
    • 18 Mar 2021 According to an Ocugen media release, the company is preparing to file an Investigational New Drug application to initiate this trial in the second half of this year.
    • 06 Nov 2020 According to an Ocugen media release, company has commenced the detailed design of its two parallel Phase 1/2a trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top